BR112022010143A2 - Inibidores de ahr e usos respectivos - Google Patents
Inibidores de ahr e usos respectivosInfo
- Publication number
- BR112022010143A2 BR112022010143A2 BR112022010143A BR112022010143A BR112022010143A2 BR 112022010143 A2 BR112022010143 A2 BR 112022010143A2 BR 112022010143 A BR112022010143 A BR 112022010143A BR 112022010143 A BR112022010143 A BR 112022010143A BR 112022010143 A2 BR112022010143 A2 BR 112022010143A2
- Authority
- BR
- Brazil
- Prior art keywords
- ahr inhibitors
- respective uses
- ahr
- inhibitors
- formulations
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962940514P | 2019-11-26 | 2019-11-26 | |
| US202063106530P | 2020-10-28 | 2020-10-28 | |
| PCT/US2020/062116 WO2021108469A1 (en) | 2019-11-26 | 2020-11-25 | Ahr inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022010143A2 true BR112022010143A2 (pt) | 2022-08-09 |
Family
ID=73856333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022010143A BR112022010143A2 (pt) | 2019-11-26 | 2020-11-25 | Inibidores de ahr e usos respectivos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230026232A1 (enExample) |
| EP (1) | EP4065090A1 (enExample) |
| JP (1) | JP2023503167A (enExample) |
| KR (1) | KR20220125232A (enExample) |
| CN (1) | CN115279347A (enExample) |
| AU (1) | AU2020391451A1 (enExample) |
| BR (1) | BR112022010143A2 (enExample) |
| CA (1) | CA3159315A1 (enExample) |
| IL (1) | IL293325A (enExample) |
| MX (1) | MX2022006312A (enExample) |
| WO (1) | WO2021108469A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019012431A (es) | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
| AU2020394424A1 (en) | 2019-11-26 | 2022-06-16 | Ikena Oncology, Inc. | Polymorphic carbazole derivatives and uses thereof |
| WO2021236717A1 (en) | 2020-05-20 | 2021-11-25 | Senda Biosciences, Inc. | Fused imidazole derivatives as ahr antagonists |
| TW202421150A (zh) * | 2022-09-14 | 2024-06-01 | 美商阿克思生物科學有限公司 | 艾魯美冷之分散體 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201103837D0 (en) * | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
| MX2019012431A (es) | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
| EP3774767B1 (en) * | 2018-04-05 | 2025-10-29 | Beth Israel Deaconess Medical Center, Inc. | Aryl hydrocarbon receptor modulators and uses thereof |
| KR20210151061A (ko) * | 2019-03-11 | 2021-12-13 | 피티씨 테라퓨틱스, 인크. | 향상된 생체이용률을 갖는 화합물 형태 및 이의 제형 |
-
2020
- 2020-11-25 EP EP20828448.9A patent/EP4065090A1/en not_active Withdrawn
- 2020-11-25 KR KR1020227021773A patent/KR20220125232A/ko not_active Withdrawn
- 2020-11-25 US US17/779,893 patent/US20230026232A1/en not_active Abandoned
- 2020-11-25 IL IL293325A patent/IL293325A/en unknown
- 2020-11-25 BR BR112022010143A patent/BR112022010143A2/pt not_active Application Discontinuation
- 2020-11-25 MX MX2022006312A patent/MX2022006312A/es unknown
- 2020-11-25 WO PCT/US2020/062116 patent/WO2021108469A1/en not_active Ceased
- 2020-11-25 AU AU2020391451A patent/AU2020391451A1/en not_active Abandoned
- 2020-11-25 CA CA3159315A patent/CA3159315A1/en active Pending
- 2020-11-25 CN CN202080092187.6A patent/CN115279347A/zh not_active Withdrawn
- 2020-11-25 JP JP2022530740A patent/JP2023503167A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020391451A1 (en) | 2022-06-16 |
| EP4065090A1 (en) | 2022-10-05 |
| WO2021108469A1 (en) | 2021-06-03 |
| CA3159315A1 (en) | 2021-06-03 |
| IL293325A (en) | 2022-07-01 |
| KR20220125232A (ko) | 2022-09-14 |
| MX2022006312A (es) | 2022-06-22 |
| JP2023503167A (ja) | 2023-01-26 |
| CN115279347A (zh) | 2022-11-01 |
| US20230026232A1 (en) | 2023-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021024108A2 (pt) | Inibidores de tead e usos dos mesmos | |
| BR112021024224A2 (pt) | Inibidores de tead e usos dos mesmos | |
| BR112022012410A2 (pt) | Degradadores smarca e usos dos mesmos | |
| BR112022011651A2 (pt) | Degradadores de irak e usos dos mesmos | |
| BR112021019748A2 (pt) | Degradadores de stat e usos dos mesmos | |
| CO2022003782A2 (es) | Inhibidores de kras g12d | |
| BR112023023223A2 (pt) | Degradadores de cdk2 e usos dos mesmos | |
| ECSP22012826A (es) | Inhibidores de parp1 | |
| CL2020000075A1 (es) | Carboxamidas como moduladores de los canales de sodio. | |
| CO2023010562A2 (es) | Degradadores irak4 y usos de los mismos | |
| BR112022018678A2 (pt) | Degradadores de mdm2 e usos dos mesmos | |
| UY38979A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio | |
| CO2020007244A2 (es) | Inhibidores de kras g12c | |
| MX2021016050A (es) | Formulaciones transdermicas. | |
| BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
| BR112021011124A2 (pt) | Anelossomos e métodos de uso | |
| MX2015011514A (es) | Compuestos de heteroarilo y sus usos. | |
| CR20150524A (es) | Compuestos de heteroarilo y sus usos | |
| MX2021007679A (es) | Anticuerpos humanos para hemaglutinina de influenza. | |
| CL2022002402A1 (es) | Inhibidores del eif4e y sus usos | |
| CO2020007895A2 (es) | Inhibidores de histona acetiltransferasa de la familia myst | |
| CL2023000491A1 (es) | Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020). | |
| MX2022006312A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. | |
| JOP20200126B1 (ar) | طرق استخدام وتركيبات تحتوي على دولاجلوتيد | |
| EA201892376A1 (ru) | Комбинированный состав трех противовирусных соединений |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |